Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period;Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment

Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period;Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment